Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Scientists have developed computer models of patients’ eyes to determine the most suitable intraocular lenses and to offer patients a visual simulation of their expected vision with these lenses. Although millions of individuals have undergone LASIK eye surgery since it…

Ectopia lentis is a term that holds a pivotal place within the realm of ophthalmology, shedding light on a unique condition that involves the lens of the eye. This condition, characterized by the displacement or dislocation of the lens from…

What Is Bullous Keratopathy? Bullous keratopathy (BK) is a pathological condition characterized by the presence of fluid-filled blisters or “bullae” on the cornea, which is the clear front surface of the eye. The main underlying factor leading to the formation…

LumiThera has been granted a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH), totaling up to $2.3 million in funding over a span of 2 years. This NIH/NEI grant is geared towards supporting…

What Is Endophthalmitis? Endophthalmitis is a rare but serious eye condition that can lead to vision loss if not promptly treated. This infection targets the interior structures of the eye, causing inflammation and potential damage. Understanding the symptoms, causes, treatment…

Corneal transplantation, also known as keratoplasty, is a common procedure performed to restore vision in individuals with corneal diseases or injuries. While the majority of corneal transplants are successful, a significant number of cases experience complications or ultimately fail. This…

Corneal opacity refers to the clouding or loss of transparency in the cornea, the clear, dome-shaped front part of the eye. It can significantly impair vision and lead to various visual disturbances. This comprehensive article aims to provide a detailed…

Since February 2023, the FDA and various companies have been actively initiating recalls of eye drops and ointments due to concerns about potential bacterial contamination. The recalls, motivated by the risk of tainted products, have been steadily increasing, underscoring the…

Astellas Pharma has signed a license agreement that grants them the rights to utilize the intravitreal retinotropic R100* vector, developed by 4D Molecular Therapeutics (4DMT). This agreement enables Astellas to target one specific genetic target associated with rare monogenic ophthalmic…

Researchers have successfully developed a groundbreaking synthetic protein to treat macular degeneration and other currently incurable eye diseases leading to blindness in millions of individuals. This pioneering drug, currently undergoing human trials, is the first of its kind. With over…